These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26412221)

  • 1. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.
    Wei X; Kenny JR; Dickmann L; Maciuca R; Looney C; Tang MT
    J Clin Pharmacol; 2016 Jun; 56(6):693-704. PubMed ID: 26412221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
    J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
    Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S
    Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis.
    Moein A; Lu T; Jönsson S; Ribbing J; Kassir N; Zhang W; Sperinde G; Zhang R; Tang M; Oh YS; Bruno R; Zhu R
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1244-1255. PubMed ID: 35851998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.
    Sun W; Lirio RA; Schneider J; Aubrecht J; Kadali H; Baratta M; Gulati P; Suri A; Lin T; Vasudevan R; Rosario M
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):734-747. PubMed ID: 33331142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
    Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.
    Motaghi E; Ghasemi-Pirbaluti M; Zabihi M
    Pharmacol Res; 2019 Jan; 139():120-125. PubMed ID: 30395950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
    D'Amico F; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
    [No Abstract]   [Full Text] [Related]  

  • 12. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis.
    Colombel JF; Ordás I; Ullman T; Rutgeerts P; Chai A; O'Byrne S; Lu TT; Panés J
    Gastroenterology; 2016 Feb; 150(2):389-95.e3. PubMed ID: 26526713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
    Zhang W; Scalori A; Fuh F; McBride J; She G; Kierkus J; Korczowksi B; Li R; Abouhossein M; Kadva A; Park KT; Tang MT
    Inflamm Bowel Dis; 2022 Sep; 28(9):1348-1356. PubMed ID: 34849918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning-Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials.
    Harun R; Lu J; Kassir N; Zhang W
    Clin Pharmacol Ther; 2024 Apr; 115(4):815-824. PubMed ID: 37828747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis.
    Kassir N; Zhu R; Moein A; Langenhorst J; Ribbing J; Zhang R; Tang MT; Oh YS; Zhang W
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1234-1243. PubMed ID: 35789549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
    Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
    J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis.
    Zhang T; Cui B; Li P; He Z; Long C; Wei L; Peng Z; Ji G; Zhang F
    PLoS One; 2016; 11(6):e0158227. PubMed ID: 27347881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Etrolizumab in the Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jaber F; Alsakarneh S; Ayyad M; Alsharaeh T; Salahat AJ; Jaber M; Kilani Y; Aldiabat M; Gangwani MK; Abboud Y; Fares A; Dahiya DS; Ahmed M; Shukla R
    Am J Ther; 2024 Sep-Oct 01; 31(5):e596-e600. PubMed ID: 39292841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.